# Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms

> **NCT06506643** · PHASE1,PHASE2 · RECRUITING · sponsor: **Vector Vitale LLC** · enrollment: 36 (estimated)

## Conditions studied

- CLL
- Solid Tumor, Adult

## Interventions

- **DRUG:** Zinc-64 Aspartate

## Key facts

- **NCT ID:** NCT06506643
- **Lead sponsor:** Vector Vitale LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-15
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06506643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06506643, "Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06506643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*